Discussion on CardioExchange: DIGging In — Three Reasons Why the Recent Digoxin Study Is Not Relevant to Readmission

To counteract recent headlines touting an analysis of the DIG trial (and the use of digoxin) as a means to reduce HF readmissions, Harlan Krumholz lays out the case for why this is incorrect. Join the conversation!

CardioExchange is an online community hosted by the New England Journal of Medicine and Journal Watch and dedicated to improving cardiac patient care. Membership is free for medical professionals.